


H K E

L F S E H K L

w

w

w



温州

院股份有限公司

Wenzhou Kangning Hospital Co., Ltd.

A joint stock limited liability company incorporated in the People's Republic of China
S)

2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

	For the year ended December 31,	
	2022 (RMB'000)	2021 (B'000)
I	1,484,903	1,274,30
	15,605	5,61
	26,574	54,831
	-10,969	40,80
	-24,221	44,036
	13,252	-3,176
	As of	
	December 31,	D 31,
	2022	2021
	(RMB'000)	(B'000)
	2,637,787	2,377,55
	1,311,885	1,077,6
	1,325,903	1,280,27
	1,201,585	1,208,26
	124,318	72,015
		</

3 BUSINESS REVIEW AND OUTLOOK

3.1 Business Review

In 2022, we continued to focus on our core business, which is the development and production of high-quality, high-performance, and high-reliability products. We have achieved significant progress in our research and development, production, and sales. Our products are widely used in various industries, including automotive, aerospace, and industrial machinery. We have also expanded our market share in the domestic and international markets. Our products are known for their excellent performance, reliability, and durability. We have a strong reputation in the industry and among our customers. We are committed to providing high-quality products and services to our customers. We will continue to invest in research and development to develop new products and technologies. We will also focus on improving our production and sales processes to enhance our efficiency and competitiveness. We believe that our strong foundation and commitment to excellence will enable us to achieve long-term success.

Our products are widely used in various industries, including automotive, aerospace, and industrial machinery. We have also expanded our market share in the domestic and international markets. Our products are known for their excellent performance, reliability, and durability. We have a strong reputation in the industry and among our customers. We are committed to providing high-quality products and services to our customers. We will continue to invest in research and development to develop new products and technologies. We will also focus on improving our production and sales processes to enhance our efficiency and competitiveness. We believe that our strong foundation and commitment to excellence will enable us to achieve long-term success.

Our products are widely used in various industries, including automotive, aerospace, and industrial machinery. We have also expanded our market share in the domestic and international markets. Our products are known for their excellent performance, reliability, and durability. We have a strong reputation in the industry and among our customers. We are committed to providing high-quality products and services to our customers. We will continue to invest in research and development to develop new products and technologies. We will also focus on improving our production and sales processes to enhance our efficiency and competitiveness. We believe that our strong foundation and commitment to excellence will enable us to achieve long-term success.

In 2022, we continued to focus on our core business, which is the development and production of high-quality, high-performance, and high-reliability products. We have achieved significant progress in our research and development, production, and sales. Our products are widely used in various industries, including automotive, aerospace, and industrial machinery. We have also expanded our market share in the domestic and international markets. Our products are known for their excellent performance, reliability, and durability. We have a strong reputation in the industry and among our customers. We are committed to providing high-quality products and services to our customers. We will continue to invest in research and development to develop new products and technologies. We will also focus on improving our production and sales processes to enhance our efficiency and competitiveness. We believe that our strong foundation and commitment to excellence will enable us to achieve long-term success.

, w
 12,172 . I 2022, 1,107 3.2 66
 I , w
 , -
 , ID-1
 ID-1 , w ID-1
 ID-1 , w ID-1
 I 2022, - w
 ,
 ,
 , w
 .

3.2 Business Highlights

I 2022, ' I.
 , w
 H E w H - H &D 2022. D 31, 2022,
 2 w 3
 ,
 I H 20 0.171 050 -1.-(B 18 67
 0

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review

For the year ended December 31, 2022, the Company's revenue was RMB1,366.8 million, an increase of 13.6% compared with RMB1,202.8 million in 2021. The increase was primarily due to the increase in the number of projects completed and the increase in the average contract value. The Company's operating profit was RMB110.0 million, an increase of 23.5% compared with RMB88.5 million in 2021. The increase was primarily due to the increase in the number of projects completed and the increase in the average contract value. The Company's net profit was RMB8.1 million, an increase of 7.3% compared with RMB7.6 million in 2021. The increase was primarily due to the increase in the number of projects completed and the increase in the average contract value. The Company's cash and cash equivalents were RMB352.1 million at the end of 2022, an increase of 17.2% compared with RMB299.8 million at the end of 2021. The increase was primarily due to the increase in the number of projects completed and the increase in the average contract value.

4.1.1 Revenue and Cost of Revenue

The Company's revenue is derived from the provision of services. The revenue is recognized when the services are completed and the payment is received. The cost of revenue is the cost of the services provided. The cost of revenue is recognized when the services are completed and the payment is received.

	For the year ended December 31,	
	2022	2021
	(RMB'000)	(RMB'000)
Revenue	1,366,817	1,202,774
Cost of revenue	110,018	71,077
	8,068	23,555
Total revenue	1,484,903	1,274,330

The Company's revenue is derived from the provision of services. The revenue is recognized when the services are completed and the payment is received. The cost of revenue is the cost of the services provided. The cost of revenue is recognized when the services are completed and the payment is received.

For the year ended December 31, 2022 (RMB'000) 2021 (RMB'000)

B L	w	(1)	1,425,005	1,226,600
			43,545	-18
			14,643	27,200
			<u>1,366,817</u>	<u>1,202,770</u>
	w			

(1) L

w

(Patients in Need)

B1,250.0, 15. % 2021, w w

. D B3.5, w w

2023. D B1.6, B12.6 w 2021,

-

	For the year ended December 31,	
	2022 (RMB'000)	2021 (RMB'000)
Treatment and general healthcare services		
Billing Revenue from owned hospitals	1,119,887	62,408
Revenue from other hospitals	770,287	658,112
Revenue from other healthcare services	349,600	304,214
Pharmaceutical sales		
Billing Revenue from owned hospitals	305,118	267,588
Revenue from other hospitals	269,828	238,112
Revenue from other healthcare services	35,290	28,670
Billing Revenue from owned hospitals	1,425,005	1,228,612
Revenue from other hospitals	1,040,115	877,112
Revenue from other healthcare services	384,890	332,884

During 2022, the Company's total revenue from owned hospitals was RMB1,425,005,000, an increase of 15.6% compared with RMB1,228,612,000 in 2021. The revenue from owned hospitals is mainly derived from the Company's hospitals, which are located in the People's Republic of China. The revenue from other hospitals is mainly derived from the Company's hospitals, which are located in the People's Republic of China. The revenue from other healthcare services is mainly derived from the Company's hospitals, which are located in the People's Republic of China.

[illegible]

D , B B20 67
 , 17.2% w 2021,
 30. %
 10.5%. ¥ B B
 w w 14.5% (2021 14.3%).

D , B
 1 64% w 2021, 78. 6% (2021 78.2%) B
 w , B
 14.0% w 2021, 21.4% (2021 21.8%) B
 w , w
 B 12.8% (2021 13.8%),
 B 71. % (2021
 6 .3%).

, w
 , ,
 , w . ¥
 w w , w

	For the year ended	
	December 31,	
	2022	2021
	(RMB'000)	(B'000)
¥	339,777	310,0 0
E	390,107	321,207
D - -	33,584	42,283
D	99,553	75,38 6
	63,747	53,470
¥	27,588	25,5 5
	85,759	6 ,081

Cost of revenue of owned hospitals

1,040,115 **8 7,112**

D , w
 B1,040.1 , 15. % w
 2021. I w () . 6%
 , () 21.5%
 w
 () - - 32.1%
 w 2021.

17
 ,
 w 32.7%
 (2021 34.6%). 17
 w 37.5% (2021 35.8%). 17
 - -
 w 12.8% (2021 13.1%).
 1%).

4.1.3 Tax and Surcharge

D ¥ , B5.0
(2021 B5.8).

4.1.4 Selling Expenses

D ¥ , B15.0
(2021 B10.3). ¥ 1.1%
w (2021 0. %).

4.1.5 Administrative Expenses

D ¥ , ¥
, ¥
w , w
¥ . ¥ w

For the year ended
December 31,
2022 2021
(RMB

4.1.6 Research and Development Expenses

D I		¥ , ¥	W W
		For the year ended December 31,	
		2022 (RMB'000)	2021 (B'000)
D I		18,899 9,803 4,053 273	16,887 8,05 3,114 302
Total		33,028	27, 6
D B33.0 w 2021. ¥ w ¥		¥ , B28.0), w 2.4% (2021 2.3%), w I	18.1%

4.1.7 Finance Expenses – Net

		For the year ended December 31,	
		2022	2021
		(RMB'000)	(RMB'000)
Interest expense		-2,762	-1,613
Interest income		-78	3
Bank charges		33,214	21,78
Interest income		11,936	14,20
		<u>2,000</u>	<u>3,042</u>
Finance expenses – net		<u>44,310</u>	<u>37,658</u>
During the year, the Group's net finance expenses were RMB44,310,000 (2021: RMB37,658,000), which were 51.1% of the Group's net profit for the year ended December 31, 2021.			

4.1.8 Investment Income

	For the year ended December 31, 2022 <i>(RMB'000)</i>	2021 (B'000) ()
Selling expenses	-15,927	- 65 66
Administrative expenses	18,063	7,075
Depreciation and amortization	<u>714</u>	<u>642</u>
	<u><u>2,850</u></u>	<u><u>6 38</u></u>

4.1.9 Credit Impairment Losses

D (2021 B2.1), B25.2, B15.

4.1.10 Asset Impairment Losses

D
w
H

,

w

B10.3

B

.

[illegible]

D B54.8), B2 6 6 (2021 w 2021. I 2022 51.5% 170.3% 57.3%, .

4.2 Financial Position

4.2.1 Inventory

D 31, 2022, B58.3 (
 D 31, 2021 B5 65),
 .

4.2.2 Accounts Receivables

D 31, 2022, B382.8
 (D 31, 2021 B311.8), 22.8%
 w D 31, 2021,
 , w .
 D ,
 w 2 (2021 37).

4.2.3 Other Receivables and Prepayments

D 31, 2022, B 6.1
(D 31, 2021 () B 1.8).

4.2.4 Other Non-current Financial Assets

D 31, 2022, w
B 3.1 (D 31, 2021 B 5.8). D
B 2.7
, w
J F .

4.2.5 Construction in progress

D 31, 2022, w B 152.5
(D 31, 2021 w B 13.8
) , w
L H , w
H , H
J H .

4.2.6 Right-of-use Assets

D 31, 2022, - - B 1 0.1
D 31, 2021 B 257.1 , - -
B 51.2 H
H .

4.2.7 Accounts Payables

D 31, 2022, B 85.8
D 31, 2021 B 6.2).

4.2.8 Receipts in Advance and Contract Liabilities

D 31, 2022, B
2 . (D 31, 2021 B 1 63).

4.2.9 Other Payables

D 31, 2022, B 72.2
D 31, 2021 () B 57.3 ,
B 17.0 L
H .

W

1

4.4 Indebtedness

4.4.1 Bank Borrowings

D 31, 2022, w B 61 65 (D 31, 2021 w B553.2), w B 02.7 B33 .

4.4.2 Contingent Liability

D 31, 2022,

4.4.3 Asset Pledge

T K H w
 L D . 82 6750, (2016) D . 82 6751, E . 00101
 (2016) E . 001012, (2021)
 E . 0081 628, (2015) . 1-1183 6
 (2015) . 1-11833, B
 D 31, 2022, S w B1 5.0

4.4.4 Lease Liabilities

D 31, 2022, B25.5 w
 w , w B171.

4.4.5 Financial Instruments

F

,

.

T

,

W

,

.

4.4.6 Exposure to Fluctuation in Exchange Rates

1. The Board of Directors of the Company has approved the proposed dividend of HKD 0.05 per share, which is subject to the approval of the shareholders at the general meeting of the Company.

5 SIGNIFICANT EVENTS

5.1 Dividend

For Board of Directors, 31, 2022. \$

5.2 Independent investigation related matters

For the year ended December 31, 2022, with the following ()
 , 1, 2022, w ()
 , w ()
 (PwC), () BD
 \$ L , w- w D 31, 2021.

For the year ended December 31, 2022, with the following ()
 (1) w , w (2) w
 w (3) w
 , 1st, 2022, ()
 Investigation Firm) ()
 w , (1) w ()
 Alleged Area I), (2) w (Alleged Area II), (3) w
 w (Alleged Area III). D 1st, 2022 \$ 23, 2022, I
 For the year ended December 31, 2022, I
 , w , w
 I , w
 , w

For the year ended December 31, 2021, 2021 27, 2022 15, 2022, 31,

For the year ended December 31, 2022, I J 30, 2022 J 10, 2023
 J 1 6, 2023, .

For the year ended December 31, 2022, w

. For Board

w

I w , B w

1. B

2. III, w .  H

3. $\bar{S}$

5.3 Correction of previous accounting errors

5.2

2021, 38 3 B D 2020

11 3 5 w 5 E ,

w 2021 w

w

5.3.1 Reasons for and details of the correction of previous accounting errors

5.3.1.1 B .18 2020 -

B

, I F

201 2020 w , B .18 B12.13 w 3 5

B 8 3 5 w 5

E D F 2020 ,

- B .18 5 w

, B . F

2020 w w

B12,878 B ,203,711 , w - w

B ,1 0,8 3, w 2021

w

B12,878, B12,878 B ,203,711 , w w

w B ,1 0,8 3.

5.3.2 The cumulative impact of the correction of previous accounting errors in the financial statements for 2020 and 2021

(1) <i>I</i> <i>5</i> 2020				
(<i>B,</i> <i>w</i>)				
Items	After restatement	Cumulative effect of error correction	Before restatement	
-	12, 87, 60	,1 0,8 8	3,7 6777	
6	83,50 ,118	,1 0,8 8	7,318,255	
	52,8 6 23	,1 0,8 8	13, 6 0 0	
w	6, 61,025	,1 0,8 8	55,770,1 02	
(2) <i>B</i> <i>5</i> 2020				
(<i>B,</i> <i>w</i>)				
Items	After restatement	Cumulative effect of error correction	Before restatement	
	8,1 6,821	-12,878	8,178,702	
1	512, 63, 617	-12,878	512, 6 61 5	
1	2,1 61,2 61,775	-12,878	2,1 61,271, 63	
	7 6 03,100	- ,203,711	85,807,111	
1	6 6077,103	- ,203,711	615,280,811	
1	1 631 ,21 6	- ,203,711	55,552, 57	
	211,85 60	,1 0,8 8	205, 66,23 6	
1				
	w			
	1,122,217,550	,1 0,8 8	1,113,05 6 6 6	
1 w ,				
	1,211, 12,55	,1 0,8 8	1,205,721, 6 5	
1				
w ,				
	2,1 61,2 61,775	-12,878	2,1 61,271, 63	

(3) RMB 2021 (B, w)

Items	After restatement	Cumulative effect of error correction	Before restatement
	2,25,888	-12,878	2,38,366
Net income	60,62,623	-12,878	60,615,501
Net income	2,377,588	-12,878	2,377,678
	57,31,528	-203,781	66,523,265
Net income	535,778,65	-203,781	535,78,376
Net income	1,07,675,868	-203,781	1,10,687,649
Net income	637,885	-12,878	650,723
	257,08,628	10,863	267,07,761
	1,208,268,7	10,863	1,219,073,038
	1,280,27,120	10,863	1,271,088,257
	2,377,588	-12,878	2,377,678

Opinions of the Independent Non-executive Directors

The Independent Non-executive Directors have reviewed the financial statements of the Company for the year ended December 31, 2021, and have concluded that the financial statements are prepared in accordance with the applicable accounting standards and are fair and reasonable.

Opinions of the Board

The Board of Directors has reviewed the financial statements of the Company for the year ended December 31, 2021, and has approved the financial statements.

Opinions of the Supervisory Committee

The Supervisory Committee has reviewed the financial statements of the Company for the year ended December 31, 2021, and has concluded that the financial statements are prepared in accordance with the applicable accounting standards and are fair and reasonable.

Opinions of the Audit Committee

“We have reviewed the financial statements of the Company and the related information, and we believe that the financial statements are fairly presented in all material aspects in accordance with the applicable accounting principles. We have also reviewed the Company’s internal control system and the related information, and we believe that the internal control system is effective in all material aspects.”

6 PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the reporting period, the Company did not purchase, sell or redeem any listed securities.

During the reporting period, the Company did not purchase, sell or redeem any listed securities. The Company’s financial statements and related information are in accordance with the applicable accounting principles and the Company’s internal control system is effective in all material aspects.

5

86

5

9 COMPLIANCE WITH THE MODEL CODE

¶
D , , . H
§
§ w w §
¶ ,
¶ .3 ,
w

7 B , w D ,
 S B - 7 w
 . 7 B D ,
 w
 S .
 7 .
 E w , ,
 B - 7 . 7 S_w S ,
 , , , ,
 , . I w ,
 w w w w .

10 EVENTS AFTER THE REPORTING PERIOD

7 w 7
 7 .

11 AUDITORS AND WORKING SCOPE

7 7 2022, w
 BD , w S B E
 w
 .
 7 ,
 7 ,
 w
 D 31, 2022 ,
 S BD ,
 2022. 7 w BD
 , H K S H K E
 E H K I BD
 w H K K S
 H K 7 S .

12 FINANCIAL REPORT

12.1 Accounting Policies

本集团自2015年1月1日起执行财政部颁布的《企业会计准则》（CAS），与财政部颁布的《企业会计准则》（CAS）一致。

本集团自2015年1月1日起执行财政部颁布的《企业会计准则》（CAS），与财政部颁布的《企业会计准则》（CAS）一致。

		Year ended December 31,	
		2022	2021
			()
I. Total revenue		1,484,903,042	1,277,430,370
I		1,484,903,042	1,277,430,370
I		—	—
IF		—	—
		—	—
		—	—
II. Total cost of sales		1,435,161,134	1,226,514,556
I		1,131,971,943	68,432,456
I		—	—
IF		—	—
S		—	—
		—	—
I		—	—
		—	—
F		4,960,286	5,754,211
		15,004,028	10,335,333
S		205,887,172	176,371,888
		33,027,988	27,621,173
IF		44,309,717	37,658,426
I	I	45,149,998	362,67,757
	I	2,761,765	1,613,677

Items	Year ended December 31,	
	2022	2021
		()
	14,907,711	13, 61 , 65
I (		
w -)	2,850,458	6 37,85
I I		
	-15,926,847	- 65 65,720
D		
	-	
F		
(w -)	-	
(w -)	-	
(w -)	-15,977,326	,517,3 1
(w -)	-25,191,541	-2,150,1 6
(w -)	-10,345,461	- 617 ,2 0
(w -)	406,185	-7 ,505
III. Operating profit		
(losses represented with “-” signs)	16,391,934	2,5 1,7 5
-	8,553,978	11,835, 32
L -	9,341,039	8, 65 6585
IV. Total profit		
(total losses represented with “-” signs)	15,604,873	5, 6 1,153
L I	26,573,712	55,830, 13
V. Net profit (net losses represented with “-” signs)		
(I)	-10,968,839	50,8 60,230
1. (		
w -)	-10,968,839	50,8 60,230
2. (		
w -)	-	
(II) w		
1. (w		
-)	-24,220,782	55,035, 5
2. - (		
w -)	13,251,944	-3,175,7 6

Items	Year ended December 31,	
	2022	2021
		()
VI. Other comprehensive income, net of tax		
(I)		
1.	—	
2.		
3.	—	
4.	—	
5.	—	
(II)		
1.		
2.	—	
3.	—	
4.	—	
5.	—	
6.	—	
7.	—	
	—	
VII.Total comprehensive income	-10,968,838	¥0,8 0,230
	-24,220,782	¥¥,035, 5
	13,251,944	-3,175,7 6
VIII. Earnings per share:		
(I) B (B)	-0.32	0. 61
(II) D (B)	-0.32	0.5

12.2.2 Annual Consolidated Balance Sheets

(B w)			
		December 31, 2022	December 31, 2021
ASSETS			
		()	()
Current assets:			
		271,094,963	188,734,846
		—	20,641,026
₱	w	—	
		—	
₱		10,641,026	10,000,000
D		—	
		—	
		382,836,691	311,757,875
		—	225,300,247
		32,201,224	11,858,427
		—	—
₱		—	—
		—	
		—	
		37,195,220	2,254,888
₱		—	6,465,824
I		58,331,397	5,651,301
		—	37,508,472
		—	
		—	
		—	
		752,325	80,686
Total current assets		793,052,846	60,602,623
			542,683,617

ASSETS	December 31, 2022	D 31, 2021 ()	J 1, 2021 ()
Non-current assets:			
☞	—		
D	—		
	—		
L -	14,000,000		
L -	143,546,246	12 ,817,77	7,81 6 31
I	—		
	—		
-	63,116,852	65,812,275	57,101, 18
I	—		107,801, 3 6
☞	695,020,441	721,81 6772	533,713,381
	152,497,400	113,7 5,718	131, 11,28 6
☒			
- -	190,403,752	257,112,270	232, 612,111
I	254,684,348	227, 1,785	1 62,53 6728
D			
☞ w	107,655,738	135,711,377	7 ,1 ,853
L -	189,586,339	150,501,038	153,550,810
D	20,682,398	11,33 6 65	110,258,388
-	13,541,047	21,0 66,387	18,708,151
Total non-current assets	1,844,734,561	1,7 68,352,3 66	1, 618,578,158
TOTAL ASSETS	2,637,787,407	2,377, 51, 8	2,1 61,2 61,775

LIABILITIES AND SHAREHOLDERS' EQUITY	December 31, 2022	D 31, 2021 ()	J 1, 2021 ()
Current liabilities:			
₱ - w	203,000,000	254,050,000	312,500,000
₱ w	—		
₱	—		
₱	13,922,929		
D	—		
	997,944		3 6080
	85,773,062	6 ,1 62,002	71, 55,8 64
	29,894,837	1 6275, 603	4, 644,278
	—	3,241	12, 65,175
₱	—		
	—		
₱	—		
₱ w	—		
E	70,588,350	60,488,184	42,785,133
₱	33,507,164	30,235,32	4 ,04 6555
	72,193,730	57,31 ,524	7 6 603,400
₱	—		
	—		
L	—		
-	147,598,324	48,240,752	35,540, 617
	—		
Total current liabilities	657,446,340	535,774, 685	60 6077,103

LIABILITIES AND SHAREHOLDERS' EQUITY	December 31, 2022	D 31, 2021 ()	J 1, 2021 ()
Non-current liabilities:			
☒	—		
L - w	391,010,000	280, 50,000	110, 2, 70
B	—		
I ☒	—		
☒	—		
L	171,437,740	231,733,7 0	1 1, 01,230
L -	42,404,938		
L -	—		
☒	—		
D	9,037,891	,31, 83	, 05,175
D	40,547,879	3 ,875,7 0	25,032,138
-	—		
Total non-current liabilities	654,438,448	5 01, 01,233	310,272,113
Total liabilities	1,311,884,788	1,0 7, 675,8 8	11631,21 6
Shareholders' equity:			
S	74,600,300	71, 00,300	71, 00,300
I	—		
☒	—		
☒	—		
L 1	855,078,533	838,1 8,3 6	81 ,30 ,0 66
	—		23,311,111
	—		
S	38,399,577	38,3 ,577	3 65 3,22
☒	—		
	233,506,534	257,0 8, 01	211,85 60
1	—		
-	1,201,584,945	1,208,2 8,8 7	1,122,217,550
	124,317,674	72,015,221	2, 66,0
Total shareholders' equity	1,325,902,619	1,280,27 ,120	1,211, 12,55
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	2,637,787,407	2,377, 51, 8	2,1 0,2 0,775

12.2.3 Annual Consolidated Statements of Cash Flow

(B w)

Items	Year ended December 31,	
	2022	2021
I. Cash flows from operating activities		
	1,452,028,763	1,211,114,151
	—	—
w	—	—
	—	—
	—	—
	—	—
,	—	—
	—	—
	—	—
	—	—
	100,857,821	6,220,745
Sub-total of cash inflows of operating activities	1,552,886,584	1,307,334,866
	613,477,475	553,860,866
	—	—
w	—	—
	—	—
w	—	—
	—	—
,	—	—
,	—	—
	525,082,523	425,383,222
☒	51,200,498	44,017,853
	135,905,523	0,175,686
Sub-total of cash outflows of operating activities	1,325,666,020	1,113,438,377
Net cash flows from operating activities	227,220,564	193,896,489

Items	Year ended December 31,	
	2022	2021
II. Cash flows from investing activities		
	—	52,117,6
	1,650,804	7,777,18
-		
	24,100,367	8,755,311
	—	I

Items	Year ended December 31,	
	2022	2021
III. Cash flows from financing activities		
	9,153,084	2, 00,000
I		
-	9,153,084	2, 00,000
w	387,500,000	550,250,000
	151,420,250	
S - w	548,073,334	553,150,000
w	324,220,000	428,342, 70
,		
I	51,554,508	30,2 7,107
-		
	56,121,295	60, 67 65 66
Sub-total of cash outflows of financing activities	431,895,803	51 ,31 6 643
Net cash flows from financing activities	116,177,531	33,833,357
IV. Effect of foreign exchange rate changes on cash and cash equivalents	78,463	-38,704
V. Net increase in cash and cash equivalents	69,861,145	-11,357,81
	188,734,846	200,0 2, 665
VI. Cash and cash equivalents at the end of the period	258,595,991	188,734,846

12.2.4 Consolidated Statement of Changes in Shareholders’ Equity

(B w)														
Items	Other equity instruments				Amount for the current period Equity attributable to owners of the parent company							Subtotal	Non-controlling interests	Total owners’ equity
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings			
I. B	74,600,300				838,165,396				38,399,577		257,098,624	1,208,263,897	72,015,224	1,280,279,121
II. B	74,600,300				838,165,396				38,399,577		257,098,624	1,208,263,897	72,015,224	1,280,279,121
III. I / ()					16,913,137						-23,592,090	-6,678,953	52,302,450	45,623,497
(I) F											-24,220,782	-24,220,782	13,251,943	-10,968,839
(II) w					12,214,419							12,214,419	43,363,507	55,577,926
1. w													43,363,507	43,363,507
2. -														
3. w ,					12,214,419							12,214,419		12,214,419

Amount for the current period
Equity attributable to owners of the parent company

Other equity instruments

Items	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings	Subtotal	Non-controlling interests	Total owners' equity
(III) D													-4,313,000	-4,313,000
1. 1,000,000 w													-	
2. 1,000,000 w														
3. 1,000,000 w ()													-4,313,000	-4,313,000
4. 1,000,000 w ,														
(IV) I														
1. 1,000,000 w														
2. 1,000,000 w ()														
3. 1,000,000 w ()														
4. 1,000,000 w														
5. 1,000,000 w														
6. 1,000,000 w														

E w

L

7

7

-

7

w

I

5

7

7

5

5

5

I. B

7, 00,300

81 ,50 ,0 66

23,311,1

3 65 3,22

205, 66,23 6

1,113,05 6 87

2, 66,00

1,205,721, 6 6

7

B

,203,7

,203,7

,203,7

II. B

7, 00,300

81 ,50 ,0 66

23,311,1

3 65 3,22

21,8 68, 77

1,122,2 0, 28

2, 66,00

1,21, 25, 37

E w

L

⌈

-

⌈

w ,

I

§

⌈

⌈

⌈

§

§

§

(III) D

1. ⌈ w

2. ⌈ w

3. ⌈ w ()

⌈

(II) I , - w

1.

-

()

2.

-

()

3.

§

⌈ - w

1,80 6348

-1,80 6348

1,80 6348

-1,80 6348

E W

L

T

§

§

—

T

V

9

I

§

(1)

§.

W

2.

(R)

B

13.

7M, 600,300.00

-1,52 6,20

-23,311,1MM

21,78^M,723

21,78^u,723

38,3 ,577

257,0 8,62%

1,208,263,87

72,015,22^M

1,280,27 ,121

12.3 Notes to the Consolidated Annual Financial Information prepared in accordance with the China Accounting Standard for Business Enterprises

12.3.1 Accounts receivable

The aging analysis of accounts receivables based on the billing date is as follows:

	December 31, 2022 RMB	December 31, 2021 RMB
1	388,961,193	303,105,710
2	4,755,920	812,850
3	3,941,367	25,870
4	3,248,300	3,140,407
5	1,932,594	
5	402,839,374	321,123,710
6		
7	20,002,683	36,835
8	382,836,691	311,757,875

Accounts receivable shown by classification of bad debt provisions

		December 31, 2022				
		Balance of carrying amount		Provision for bad debts		
		Amount	Proportion (%)	Amount	Percent of provision (%)	
					Book value	
I	W	18,221,976	4.52	12,514,143	68.68	5,707,833
		18,221,976	4.52	12,514,143	68.68	5,707,833
	W	384,617,398	95.48	7,488,540	1.95	377,128,858
		384,617,398	95.48	7,488,540	1.95	377,128,858
T		402,839,374	100.00	20,002,683	5.0	382,836,691
		B	D	31, 2021 (	)	
		₹	₹	₹	₹	
			(%)		(%)	B
I	W	7,27, 78	2.2 6	4,5 0,28 6	63.33	2, 67, 6 2
		7,27, 78	2.2 6	4,5 0,28 6	63.33	2, 67, 6 2
	W	313,875,732	7.74	4,775,54	1.52	30 ,100,183
		313,875,732	7.74	4,775,54	1.52	30 ,100,183
T		321,123,710	100.00	3 6,835		311,757,875

12.3.2 Accounts payable

		RMB	US\$
		December 31,	D
		2022	31,
		RMB	2021
			<i>B</i>
		84,193,739	6, 38, 475
		1,161,389	2,7 67, 0 6
		71,969	1 68,510
		345,965	287,111
		85,773,062	6 ,1 62,002

12.3.3 Revenue and cost of sales

Analysis of revenue and cost of sales

	Year ended December 31, 2022		D 2021	
	Revenue	Cost		
	1,366,816,938	1,040,114,650	1,202,774,378	877,111,636
	<u>118,086,104</u>	<u>91,857,293</u>	<u>1,184,655,2</u>	<u>71,320,820</u>
₹	<u>1,484,903,042</u>	<u>1,131,971,943</u>	<u>1,27,130,370</u>	<u>8,132,156</u>

Breakdown of revenue:

		Year ended December 31, 2022	Year ended December 31, 2021
		Revenue	
I	☒	1,366,816,938	1,202,774,378
	☒	305,118,303	267,588,282
		1,061,698,635	35,186,096
I	☒	118,086,104	4,655,212
		85,464,736	51,613,422
		3,000,000	2,702,277
		8,067,969	7,515,327
		—	1,603,548
		21,553,398	1,651,338
		<u>1,484,903,042</u>	<u>1,274,303,370</u>

12.3.4 Expenses by nature

		Year ended December 31, 2022	Year ended December 31, 2021
E	w	538,910,495	435,675,572
☒		417,971,255	353,105,212
		—	15,204,373
D		53,029,785	45,173,131
D	- -	38,189,336	45,435,381
		22,991,164	15,010,680
	-	46,397,647	38,371,181
H		17,904,619	15,472,885
		66,553,544	57,050,466
		29,928,936	24,061,566
		23,086,081	21,047,712
☒		27,657,239	25,603,836
		28,302,685	13,820,362
		6,366,300	1,222,000
☒		3,526,993	2,033,333
☒		5,332,488	4,416,545
		8,492,201	3,312,808
S	-	12,214,419	15,327,752
		39,035,944	43,866,152
		<u>1,385,891,131</u>	<u>1,183,101,101</u>

12.3.7 Income tax expenses

Table of income tax expenses

	Year ended December 31,	
	2022	2021
D	40,192,565	26,118,820
	-13,618,853	27,110,3
F	26,573,172	53,830,13

Reconciliation between total profit and income tax expenses

	Year ended December 31,	
	2022	2021
		()
F	15,604,874	5,611,13
I	3,028,480	21,762,76
I	7,125,277	1,508,267
	-3,896,947	-2,51,77
I	-5,563,847	-283,550
I	1,736,913	1,012,268
I	137,339	-3,07,22
I		
	31,726,873	10,7,555
0 5 5 8 F (	13 1 17 50,	. 38 w

12.3.8 Dividend

	31, 2023,	B	D	31, 2022. ₺
₺			₺	600 .
	2 6 2022,	B	D	31, 2021. ₺
₺	w	D	₺	1 6 2022.
2021				

13 CONTINUED SUSPENSION OF TRADING

5 E , w 00 . . 1, 2022. 7 H K

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

14 DEFINITIONS

2022

B
H

B H ., L . (北京怡寧醫院有限公司),
17, 2015, -w w

B
H K K H ., L . (蒼南康寧醫院有限公司),
15, 2012, J
w - w

醫院有限公司), 16 2020, 淳安康寧黃鋒

H K H E S w H K L (S 2120) B

[illegible]

D () ()

D § () () , w

B B1.00 , w

w

H K H ., L . (淮南康寧醫院有限公司),
H 22, 2017, S_w -w

J H J H 7 ., L . (浙江傑翎健康科技有限公司) (I 7 ., L . (杭州耶利米信息科技有限公司)),
D 27, 2018, w -w

J S J S H ., L . (縉雲舒寧醫院有限公司),
H S 15, 201 , 7 -w w

J 7 J H I E I 7 7 (L 7) (重慶金浦醫療健康服務產業股權投資基金合夥企業(有限合夥)),
7 22, 201 6 w 3.5% 61% J 7

L L H ., L . (溫州鹿城怡寧醫院有限公司),
H 2, 2020, 7 w -w

L L H ., L . (臨海慈寧醫院有限公司),
H 11, 2020, 7 w D w -w

L I S 7 10 H D K L H ., L . (南京怡寧醫院有限公司),
H 22, 2018, 7 w -w w

7 H 7 H ., L . (平陽長庚怡寧醫院有限公司),
7 J 14, 2021, 7 w -w

7 H H ., L . (浦江怡寧黃峰醫院有限公司),
H 3, 2018, 7 w -w S_w

57

■

■

■

H

., L . (溫

嶺南方精神疾病專科醫院有限公司),

■

w

J

20, 2018,

-w

w

■

E

H

■

E

H

., L . (溫州甌海

怡寧老年醫院有限公司),

8, 2021,

-w

w

w

I

■

H

■

I

H

(■)

., L . (怡

寧心理互聯網醫院(溫州)有限公司),

■

w

10, 2020,

,

w

- w

H

K

K

H

., L . (永嘉康寧醫院有限公

司),

D

12, 2012,

■

w

,

w

- w

H

K

K

H

., L . (樂清康寧醫院有限公

司),

S

3, 2013,

■

w

,

w

- w

H

H

I

., L . (樂清怡寧中西醫結合醫院有限

公司),

■, 200 6,

■

w

,

w

- w

■

有限公司)

H

w

L

(樂清邦爾中西醫結合醫院

%

B

B

Wenzhou Kangning Hospital Co., Ltd.

GUAN Weili

■, 1st, 2023

■

L

-

D

,

D

.

H

■

.

J

H

.

LI

.

.

■